PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us

The UPC’s first decision on infringement by equivalence (Plant-e v Bioo, UPC_CFI_239/2023)

  • Sector: Chemistry
  • 28th February 2025
 

In Plant-e v Bioo the UPC provided its first decision addressing the doctrine of equivalents in patent infringement proceedings (UPC_CFI_239/2023). The Local Division of the Hague set out a novel four-part test for assessing equivalence drawn from various national jurisdictions. The test appears relatively patentee-friendly, with the Local Division finding infringement of the claims despite the alleged infringement lacking explicit features of the invention as defined by the claims.

Legal background: Equivalence around Europe

The Unified Patent Court Agreement (UPCA) contains no specific provisions on the doctrine of equivalence. However, the Local Division of the UPC in this case found that Article 2 of the Protocol on the interpretation of Article 69 EPC makes it clear that equivalence should be considered when assessing the scope of protection of a European patent: “For the purpose of determining the extent of protection conferred by a European patent, due account shall be taken of any element which is equivalent to an element specified in the claims.” Beyond this high-level guidance from Article 2 of the Protocol, the UPC faces the challenge of developing its own approach to assessing infringement by equivalence. 

Case details: Plant-based fuel cells 

The dispute in UPC_CFI_239/2023 concerned EP2137782, owned by Plant-e Knowledge B.V., relating to a device and method for converting light energy into electrical energy using plants in microbial fuel cells (P-MFCs). The patent claimed a method requiring a living plant to be located in an anode compartment of the fuel cell, with micro-organisms living around the plant’s root zone. Plante-e brought an infringement action against Arkyne Technologies SL (aka Bioo). Bioo counterclaimed for revocation. The case was heard by the Local Division of the UPC in The Hague. The panel of judges comprised Presiding Judge Edger Brinkman (Netherlands), Legally qualified judge Samuel Granata (Belgium), Technically qualified judge Simon Walker and Judge-rapporteur Margot Kokke. 

The patent in question (EP2137782) particularly related to devices and methods of generating electricity from living plants using microbial fuel cells (MFCs). MFCs using microorganisms to convert organic compounds into electrical energy were known in the art. However, these conventional MFCs required external supply of organic material as fuel, creating sustainability issues. EP2137782 purported to solves this problem by incorporating a living plant directly into the MFC system. The plant converts light energy into organic material through photosynthesis. This organic material is then released by the roots into an anode compartment containing special “anodophilic” microorganisms. These microorganisms oxidize the organic material from the plant, generating electrons that are collected at the anode to produce electrical energy.

The patent claimed a device comprising a reactor having an anode compartment and cathode compartment, the anode compartment containing: a) an anodophilic microorganism capable of oxidizing an electron donor compound b) a living plant capable of converting light energy by photosynthesis into the electron donor compound, wherein “the root zone of the plant is essentially placed in the anodic material”. The patent was granted in 2017 and, notably, no opposition was filed at the EPO. 

 Plant-e alleged that Bioo’s products, in particular the “Bioo Panel” containing a two-compartment system with plants separated from the anode, infringed the patent. The Bioo Panel is a device for generating electricity using plants and soil. The panel consists of two compartments assembled in a single device. The upper compartment contains soil and optionally plants that grow naturally in the installation environment. The lower compartment contains what Bioo terms a “biological battery”, comprising an anode and cathode separated by soil. Rather than having the plant roots directly in contact with the anode (as in Plant-e’s patent), the two compartments are separated by a filter. However, the compartments are connected such that rainwater and irrigation can leach nutrients and microorganisms from the soil in the upper compartment through to the lower compartment containing the anode. 

The issue in this case was whether the Bioo panel two-compartment design, which deliberately avoided direct contact between plant roots and the anode, nonetheless infringed Plant-e’s patent claims requiring the “root zone of the plant to be essentially placed in the anodic material.” Bioo argued that its design was specifically developed to avoid the problems that occur when roots directly contact the anode, such as damage to the anode and disruption of the anaerobic conditions required for electricity generation. Indeed, Bioo had filed its own patent application (WO 2022/058500) describing these advantages of its two-compartment design.

The UPC’s 4-question approach to equivalence

The UPC had to consider whether, despite these deliberate design choices to separate the roots from the anode, the Bioo Panel still fell within the scope of Plant-e’s patent under the doctrine of equivalents. Critical to this assessment was whether organic material produced by the plants in the upper compartment could still reach the anode compartment to fuel electricity generation, even without direct root contact. 

The UPC faces an interesting challenge in developing its approach to equivalence. Whilst Article 2 of the Protocol to Article 69 EPC requires equivalents to be considered, it provides no guidance on how to assess them. The court therefore needed to craft its own test. The court proposed a novel four-part test. According to the decision, “the test is based on the case law in various national jurisdictions, as proposed by both parties in this case” (para. 88). Under this new test, a variation is deemed equivalent if all four questions are answered affirmatively:

“A variation is equivalent to an element specified in the claim if the following four questions are answered in the affirmative: 

i. Technical equivalence: does the variation solve (essentially) the same problem that the patented invention solves and performs (essentially) the same function in this context? 

ii. Fair protection for patentee: is extending protection proportionate to fair protection?

iii. Reasonable legal certainty: does the skilled person understand from the patent that the scope is broader than literally claimed? 

iv. Is the allegedly infringing product novel and inventive over the prior art?“

Applying its new test, the court found that whilst Bioo’s two-compartment system did not literally infringe as the plant was not in the anode compartment. However, the Local Division found that the alleged infringement was nonetheless equivalent. 

i. Technical equivalence: does the variation solve (essentially) the same problem that the patented invention solves and performs (essentially) the same function in this context? 

The Local Division found that the Bioo Panel was technically equivalent to the patented invention because it solved the same problem and performs the same function, i.e. using a plant as part of the reactor to provide organic material for generating electricity, making the device substantially independent of external fuel. Whilst the Bioo Panel used a different two-compartment setup, the Local Division deemed this difference immaterial since it didn’t affect the plant’s core function. For the Local Division, based on the evidence submitted, despite the different physical configuration of the device, the underlying technical solution remained the same. The Local Division therefore answered “yes” to this question. 

ii. Fair protection for patentee: is extending protection proportionate to fair protection?

The Local Division also found that extending the scope protection of the patent through equivalence to cover the Bioo Panel was proportionate and fair. The Local Division particularly found that Plant-e had made a significant contribution to the field by creating “a new category of microbial fuel cells, by introducing a plant into the device/reactor and to obtain electricity from organic material originating from the photosynthesis by that plant and thus from light energy” (para. 98). Given this substantial contribution, the Local Division deemed “a fairly broad scope of protection” appropriate, especially since the Bioo Panel implemented “exactly that principle” (para. 98) and the modification represented by the Bioo Panel would be obvious to a skilled person in view of the disclosure in the patent. 

iii. Reasonable legal certainty: does the skilled person understand from the patent that the scope is broader than literally claimed? 

In their answer to the third question, the Local Division found that the requirement of legal certainty was met because “the skilled person understands that the patent claim leaves room for equivalents because the teaching of the patent is (clearly) broader than the wording of the claim and there is, still in the eyes of the skilled person, no good reason to limit the scope of protection of the claim to a (method using a) device as claimed” (para. 100). Specifically, the court determined that “[t]he teaching of the patent is to add a plant to a MFC to provide (additional) feedstock to make the MFC independent of externally provided feedstock. The skilled person will understand that the variation of the Bioo Panel is another way to obtain this result in a similar way” (para. 100, emphasis added). Thus, the Local Division concluded that a skilled person would therefore understand from the patent that its scope extended beyond the literal claim language to cover equivalent ways of achieving the same core teaching. As such, for the Local Division, the requirement for legal certainty was satisfied.

iv. Is the allegedly infringing product novel and inventive over the prior art?“

The Local Division only briefly addressed this final question, which the Local Division equates to confirming that there is no successfulGillette/Formsteindefence. The Local Division noted that “[a]t the priority date, the Bioo Panel would have been novel and inventive over the prior art because of the introduction of a plant as part of the device as a supplier of additional fuel for the battery/reactor. Parties did not argue otherwise (or differently)” (para. 101). As such, the Local Division found the answer to the question was “yes”. 

The Local Division concluded that that Bioo both directly and indirectly infringed the patent. The Local Division also considered the validity of the patent, finding that it was novel and inventive. The Local Division awarded Plant-e preliminary damages of EUR 35,000 and for Bioo to pay legal costs. 

Final thoughts

The decision in UPC_CFI_239/2023 provides some indication on how the UPC will approach equivalence. The Local Division’s approach represents a relatively patentee-friendly approach to infringement by equivalence. The new four-part test proposed by this Local Division thus appears to set a relatively low bar at the UPC for finding equivalence compared to some national courts, although I would be interested to hear readers views. Of course, there in also plenty of scope for the other divisions of the UPC to develop (or even reject) the test proposed by this Local Division. The decision is merely the first indication of how the UPC may approach this controversial and jurisdictionally variable aspect of patent law. 

Related insights...

Alexion’s Soliris sequence error saga (Alexion v Samsung Bioepis [2025] EWHC 1240)

  • 4th June 2025
The recent UK High Court decision in Samsung v Alexion [2025] EWHC 1240 (Pat) is a stark reminder that you can never be too careful with patent sequence data. Mr Justice Meade’s ruling in this case highlights that simple mistakes in the sequence information can be fatal for both the enforcement and validity of the claims. The case, relating…

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

  • 27th May 2025
Author: Rose Hughes Last week, I had the pleasure of participating in the 2025 C5 Annual Forum on Pharma & Biotech Patent Litigation in Europe, held in Amsterdam. The conference was a reminder (if ever one was needed) that patent law never stands still. There was a lot of food for thought from the various…

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • 20th May 2025
In the new AI-age, where Large Language Models (LLMs) like ChatGPT can generate sophisticated textual answers in seconds, the relevance of AI to the patent industry is an active area of debate. The recent EPO Board of Appeal in T 1193/23 specifically questioned the reliability of LLM-generated interpretations for technical terms within patent claims. Central to this case…

First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024)

  • 19th May 2025
The complexities of patenting new uses for known medical substances were recently considered by the Düsseldorf Local Division in the UPC’s first decision on second medical use claims. The case of Sanofi v Amgen (UPC_CFI_505/2024) specifically addressed the novelty and infringement standards applicable to second medical use claims. The case is part of the long-running dispute between Sanofi and…

Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

  • 9th May 2025
In recent years, Novo Nordisk’s weight loss drug semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, has become a pharmaceutical phenomenon. As with most successful pharmaceutical products, the remarkable success of semaglutide means we can also expect some high profile IP disputes. In jurisdictions lacking provisions for patent term extension, semaglutide is expected to face generic challenge…

The plausibility of diagnostic inventions: No data, no patent (T 0589/22)

  • 30th April 2025
In T 0589/22, the Board of Appeal revoked a patent for an in vitro diagnostic method on the basis that the claimed diagnostic effect was not rendered plausible. According to the Board of Appeal’s interpretation of the claims, none of the examples in the patent related to the population of subjects defined by the claims.…

AlphaFold: From Nobel Prize to drug-discovery gold mine?

  • 29th April 2025
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst large language models such as ChatGPT can write poems and make pretty pictures, AlphaFold has the potential to dramatically impact the life-and-death world of drug discovery. AlphaFold represents truly ground-breaking science for which its…

G 2/21 applied to software inventions (T 0687/22)

  • 29th April 2025
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in T 0687/22 links the case law from G 1/19 and G 2/21 to highlight the importance of establishing a credible technical effect of software invention. The Patentee in the case made several attempts to formulate an objective technical problem solved by the invention based…

Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22)

  • 29th April 2025
IP strategy for cell therapy also has unique challenges. The patent at issue in T 1259/22, although relatively old (expiring August 2024 with SPCs), nonetheless highlights some of the key challenges for cell therapy IP strategy.

Beyond the process: Securing robust IP protection for cell therapies

  • 29th April 2025
Cell therapy represents one of the most exciting fields of innovation, with the potential to provide long-term cures for previously incurable diseases. However, unlike traditional pharmaceuticals, these “living medicines” present unique IP challenges that can make or break a biotech’s future.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Contact Us